The worldwide immunoassay market is predicted to grow at a CAGR of 7.5% from 2021 to 2028, succeeding to $46.5 billion by 2028.
After succeeding in a thorough secondary and first analysis and in-depth evaluation of the market situation, the report critically sums up the business drivers, constraints, challenges and alternatives.
Expansion within the immunoassay market is primarily attributed to the increasing prevalence and prevalence of infectious diseases, technological advances in immunoassays, increasing use of immunoassays in oncology and drug and alcohol testing, and the emergence of immunoassays.
Within the immunoassay kits and reagents market, mostly by type, the ELISA kits and reagents segment is expected to account for the most significant share of the immunoassay market in 2021. The continued growth of recent biomarkers and the adoption of automated platforms for ELISA are anticipated elements to expand the adoption of this segment.
Based mostly on platforms, the chemiluminescence immunoassay platform section is projected to account for the most significant portion in 2021, as a result of the increasing prevalence of acute and electrical diseases, rapid technological advances and the extreme specificity of chemiluminescence platforms.
Based mostly on the Finnish consumer, the Diagnostic Reference Laboratories section is projected to account for the most significant share in 2021. The factors that contribute in large part to this section include the increasing technological advances for immunoassay diagnostic platforms in laboratories, the rise in various types of examinations. Diagnostic laboratories, increasing laboratory automation, availability of well-equipped immunoassay techniques and increasing prevalence of infectious diseases.